Site-specific attachment to recombinant antibodies via introduced surface cysteine residues

• Published in: Protein engineering 1990-08, Vol.3 (8), p.703-708
• Main Authors: Lyons, Alan, King, David J., Owens, Raymond J., Yarranton, Geoffrey T., Millican, Andrew, Whittle, Nigel R., Adair, John R.
• Format: Article
• Language: English
• Subjects: Algorithms; Animals; Antibodies, Monoclonal - analysis; Antibodies, Monoclonal - genetics; Antibodies, Monoclonal - immunology; antibody; Binding Sites; Biological and medical sciences; Biotechnology; Cell Line; Chromatography, High Pressure Liquid; cysteine; Cysteine - analysis; Fundamental and applied biological sciences. Psychology; Immunoglobulin G - analysis; Immunoglobulin Heavy Chains - analysis; immunoglobulins; Methods. Procedures. Technologies; Molecular Structure; Mutagenesis, Site-Directed; Protein Engineering; radio-labelling; recombinant; Recombinant Proteins - analysis; Recombinant Proteins - genetics; Recombinant Proteins - immunology; site-specific; Sulfhydryl Compounds
• ISSN: 1741-0126; 0269-2139; 1741-0134; 1460-213X
• DOI: 10.1093/protein/3.8.703

Many diagnostic and therapeutic applications of monoclonal antibodies require the covalent linking of effector or reporter molecules to the immunoglobulin polypeptides. Existing methods generally involve the non-selective modification of amino acid side chains, producing one or more randomly distributed attachment sites. This results in heterogeneous labelling of the antibody molecules and often to a decrease in antigen-binding due to the modification of residues close to the antigen-binding site. We report a novel strategy for site-specifically labelling antibodies through surface cysteine residues. Examination of molecular structures was used to identify amino acids of the CH1 domain of the IgG heavy chain that were accessible to solvent but not to larger molecules. Site-directed mutagenesis was used to substitute cysteine residues at these positions in the heavy chain of a mouse/human chimaeric version of the tumour-binding monoclonal antibody, B72.3. Expression of the modified antibody genes in mammalian cells yielded correctly assembled proteins that had thiol groups in pre-determined positions and showed no loss of antigen-binding activity. One of the mutants was used to demonstrate the site-specific attachment of a radio-iodinated ligand to the chimaeric B72.3 antibody.